The FuSion Program: A Prospective and Multicenter Cohort Study of Pan-Cancer Screening in Chinese Population
A Prospective, Multicenter, Noninterventional Cohort Study of Muti-Omics Models for Pan-Cancer Screening
Singlera Genomics Inc.
60,000 participants
Jul 6, 2021
OBSERVATIONAL
Conditions
Summary
The integrative study by Fudan and Singlera for cancer early detection(The FuSion Program ) will evaluate sensitivity,specificity and positive/negative predictive value of the screening model jointly developed by FuDan University and Singlera in a 2-year follow-up corhort including 10,000 persons in routine annual physicals from dozens of hospitals. The multi-omics model for pan-cancer screening will be developed in a 3-year follow-up corhort including 50,000 natural persons in community containing genetic information of tumor families, assessment of epidemiological risk factors, tumor markers, proteomics, genomics and DNA methylation. After optimizing, the ability of this model will be validated in the Taizhou corhort in reality.
Eligibility
Inclusion Criteria5
- Take physical examinations in our research centers and have no cancer history;
- "Population Health tracking Survey - simplified version of the questionnaire" must be filled according to the research program and an annual physical examination can be received as follow-up ;
- Timely feed back the information related to tumor diagnosis in other hospitals to the investigator during the program;
- Have no birth plan for the last 3 years;
- Fully understand the study and voluntarily sign the informed consent.
Exclusion Criteria6
- Have been diagnosed with esophageal cancer, gastric cancer, colorectal cancer, liver cancer, lung cancer, pancreatic cancer, breast cancer (including non-primary, such as recurrence, metastasis or other complications) and other malignant tumors;
- Received blood transfusion, transplantation and other major operations within 3 months;
- Participated in other interventional clinical researchs within 3 months;
- Pregnant or lactating women;
- Patients with autoimmune diseases, genetic diseases, mental diseases/disabilities and other diseases considered unsuitable for the study by the investigator;
- Due to poor compliance, the researcher judged that the study could not be completed.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05159544